Company Filing History:

8 out of 2,198

Smithkline Beecham Corporation

patents

4 out of 207

Smithkline Beckman Corporation

Years Active: 1987-2006

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7053099 - 3,4-dihydro-(1H)quinazolin-2-one compounds as CSBP/p38 kinase inhibitors (2006-05-30),

2. 7053098 - 3,4-Dihydro-(1H) quinazolin-2-one compounds as CSBP/P38 kinase inhibitors (2006-05-30),

3. 6982270 - 3,4-dihydro-(1H)quinazolin-2-one compounds as CSBP/p38 kinase inhibitors (2006-01-03),

4. 6759410 - 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors (2004-07-06),

5. 5981538 - Methods of treating psoriasis employing substituted azaspiranes (1999-11-09),

6. 5929096 - Method for treating atopic dermatitis and contact dermatitis (1999-07-27),

7. 5824696 - Medicaments (1998-10-20),

8. 5317019 - Inhibition of interleukin-1 and tumor necrosis factor production by (1994-05-31),

9. 5134150 - Inhibition of the 5-lipoxygenase pathway (1992-07-28),

10. 4794114 - Inhibition of interleukin-1 production by monocytes and/or macrophages (1988-12-27),

11. 4780470 - Inhibition of interleukin-1 by monocytes and/or macrophages (1988-10-25),

12. 4778806 - Inhibition of interleukin-1 production by monocytes and/or macrophages (1988-10-18),

13. 4686231 - Inhibition of 5-lipoxygenase products (1987-08-11),

Title: Don Edgar Griswold: A Pioneer in Kinase Inhibitor Development

Introduction

Don Edgar Griswold, an accomplished inventor based in North Wales, Pennsylvania, has made significant contributions to the field of pharmaceutical sciences through his innovative work. With a total of 13 patents to his name, Griswold has specialized in developing compounds that target specific kinases, which play crucial roles in various cellular processes.

Latest Patents

Among Griswold's most recent patents are his groundbreaking work on 3,4-Dihydro-(1H) quinazolin-2-one compounds as CSBP/P38 kinase inhibitors. These novel substituted quinazoline compounds and compositions show promise for therapeutic applications as CSBP/p38 kinase inhibitors. The repetition of this significant innovation highlights the importance of these compounds in targeting pathways involved in inflammatory responses and other diseases.

Career Highlights

Throughout his career, Don Edgar Griswold has been affiliated with prestigious organizations that have shaped his professional journey. Notably, he has worked with the SmithKline Beecham Corporation and SmithKline Beckman Corporation, where he collaborated on various research and development projects. His role in these companies advanced the field of drug development and showcased his expertise in molecular design and therapeutic applications.

Collaborations

Griswold's innovative journey has seen him collaborate with notable coworkers, including Paul E. Bender and Nabil Hanna. These collaborative efforts have fostered a rich exchange of ideas and research advancements, propelling the development of novel therapeutic agents and kinases.

Conclusion

Don Edgar Griswold continues to stand out as a prominent figure in the field of pharmaceutical inventions. His contributions, evidenced by a robust portfolio of patents and impactful collaborations, mark him as an essential player in the ongoing pursuit of innovative solutions for medical challenges. The significance of his work in developing kinase inhibitors is expected to have lasting impacts on future therapeutic strategies.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.